Paul G. Sator
Hietzing, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.
Journal: Acta dermato-venereologica
Published: April 07, 2026
Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study.
Journal: The British journal of dermatology
Published: February 08, 2025
Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study.
Journal: The Journal of dermatological treatment
Published: October 17, 2024
Author Correction: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Journal: Scientific reports
Published: March 27, 2024
S1 guidelines for the management of postviral conditions using the example of post-COVID-19
Journal: Wiener klinische Wochenschrift
Published: June 14, 2023
Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: January 22, 2023
Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: January 22, 2023
Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.
Journal: Therapeutic advances in chronic disease
Published: September 16, 2022
Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions.
Journal: Case reports in dermatology
Published: May 04, 2022
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Journal: Scientific reports
Published: March 07, 2022
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 09, 2021
Last Updated: 09/26/2026